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Abstract
Background: Supraclavicular lymph node (SCLN) biopsies play an important role in diagnosing and staging lung
cancer. However, not all patients with SCLN metastasis can have a complete resection. It is still unknown whether
SCLN incisional biopsies affect the prognosis of non-small cell lung cancer (NSCLC) patients.
Methods: Patients who were histologically confirmed to have NSCLC with SCLN metastasis were enrolled in the
study from January 2007 to December 2012 at Guangdong Lung Cancer Institute. The primary endpoint was OS,
and the secondary endpoints were complications and local recurrence/progression.
Results: Two hundred two consecutive patients who had histologically confirmed NSCLC with SCLN metastasis
were identified, 163 with excisional and 39 with incisional biopsies. The median OS was not significantly different
between the excisional (10.9 months, 95% CI 8.7–13.2) and incisional biopsy groups (10.1 months, 95% CI 6.3–13.9),
P = 0.569. Multivariable analysis showed that an Eastern Cooperative Oncology Group (ECOG) performance status
(PS) ≥2 (HR = 2.75, 95% CI 1.71–4.38, P < 0.001) indicated a worse prognosis. Having an epidermal growth factor
receptor (EGFR) mutation (HR = 0.58, 95% CI 0.40–0.84, P = 0.004) and receiving systemic treatment (HR = 0.36, 95%
CI 0.25–0.53, P < 0.001) were associated with a favorable OS. Neither the number (multiple vs. single) nor site
(bilateral vs. unilateral) of SCLNs was associated with an unfavorable OS, and SCLN size or fixed SCLNs did not
affect OS.
Conclusions: SCLN incisional biopsies did not negatively influence the prognosis of NSCLC patients. It was safe
and feasible to partly remove a metastatic SCLN as a last resort in advanced NSCLC.
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Background
Lung cancer threatens human health greatly, and patients
who present with supraclavicular metastasis are classified
as stage IIIB or IV and are therefore not considered candi-
dates for surgical treatment [1]. Supraclavicular lymphade-
nectomy plays an important role in diagnosing and staging
lung cancer. There were no evidences on the survival
advantage of excision on supraclavicular lymph nodes
in advanced lung cancer patients. The advantage of
lymphadenectomy is that we could get the accurate N
stage. Besides, it provides more tissue than a needle biopsy
for detection of gene profile with less complication. In
clinical practice, we prefer to perform complete exci-
sion because of the tumor-free principle. Unfortunately,
complete excision cannot be performed on all patients.
Partial removal of the tumor is inevitable when metastatic
lymph nodes are too large, in an inaccessible location, or
when they tightly adhere to important adjacent structures
with unclear margins.
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Over the past decades, the question of whether an inci-
sional biopsy affects the prognosis of melanoma patients
has been very controversial, with evidence suggesting
there appears to be little difference [2–4]. For early stage
lung cancer, radical lung resection combined with system-
atic nodal dissection is recommended, and is associated
with a better prognosis [5, 6], while incomplete resection
(R1/R2) is associated with a higher incidence of local re-
currence and a worse prognosis [7–9], possibly because of
cancer cell seeding and dissemination during the process
of incomplete resection. However, prognoses are different
for advanced lung cancer. Metastasectomy or other local
therapy in malignancy was often used in certain situations,
and the major goal of local treatment was debulking rather
than eradication [10]. Though supraclavicular lymph node
(SCLN) resection as a biopsy method was widely used in
practice; there were few reports about whether partial re-
moval of metastatic SCLNs would lead to a worse progno-
sis in lung cancer, which is of concern for both doctors
and patients.
The aim of the current study was to explore the influence




Patients who were histologically confirmed with NSCLC
with SCLN metastasis were enrolled into the study from
January 2007 to December 2012 at Guangdong Lung
Cancer Institute (GLCI). Patient eligibility criteria were
as follows: (1) Histological confirmation of NSCLC. (2)
Confirmation of metastatic NSCLC through supraclavicular
lymphadenectomy. (3) No other concomitant malignancies.
The ethics committee of Guangdong General Hospital ap-
proved the study, and informed patient consent was waived
because of the retrospective nature of the study. Statisti-
cians acquired follow-up information every 3 months from
the registries of the GLCI.
Supraclavicular lymphadenectomy
SCLNs were diagnosed using palpation or imaging at the
first visit and then histologically confirmed after resection.
Three residents performed the supraclavicular lymphade-
nectomy following the principles below: First, metastatic
lymph nodes should be completely removed. Second, one
or more lymph nodes should be removed with intact cap-
sule when multiple lymph nodes were enlarged and re-
moving all of them was not feasible. Either complete
resection or intact removal of one of several lymph nodes
was defined as an excisional biopsy. Third, an incisional
biopsy should be performed only as a last resort when an
excisional biopsy was impossible.
Statistical analysis
Pearson’s chi-square test was used to compare the fre-
quency of the baseline data. The Kaplan–Meier method
was used to estimate survival outcomes, and the differ-
ence in survival was compared using the log-rank test.
Multivariable Cox regression was used to evaluate inde-
pendent prognostic factors associated with overall sur-
vival (OS). P < 0.05 was deemed to be statistically
significant. All P values and 95% confidence intervals
(95% CI) were two-sided. Statistical analyses were done
using the Statistic Package for the Social Sciences (SPSS,
version 13.0). The primary endpoint was OS, which was
defined as the interval from initial pathologic diagnosis
to death. The secondary endpoints were complications
and local recurrence/progression. Local recurrence/pro-
gression was defined as relapse of lymph nodes on the
biopsy side in the excisional biopsy group or obviously
enlarged in the incisional biopsy group after biopsy.
Results
From January 2007 to December 2012, we identified 202
consecutive histologically confirmed NSCLC patients with
SCLN metastasis, 163 had excisional and 39 had incisional
biopsies. Baseline demographic and clinical characteristics
are shown in Table 1. The median age was 58 years (range
26–85). Most patients (164/202, 81.2%) were stage IV at
initial diagnosis and were diagnosed with adenocarcin-
omas (169/202, 83.7%). Patients receiving an incisional bi-
opsy were more likely to be male (P = 0.003), and a
current or ever-smoker (P = 0.008), with larger lymph
node size (P < 0.001) and fixed lymph nodes (P < 0.001).
Most patients (86.1%, 174/202) were treatment-naïve
at the time of biopsy. Of the patients, 75.7% (153/202)
received systemic treatment; 77.9% in the excisional vs.
66.7% in the incisional biopsy group. There was no signifi-
cant difference in receiving systemic treatment between
the two groups; P = 0.141. We noted that 49 patients
(24.3%) had no record of receiving any antitumor treat-
ment during their lifetimes, in most cases (57.1%) because
of pessimistic attitude or financial problems and in nine
cases (18.4%) because of poor performance status (PS).
Twenty-three patients (11.4%) had received SCLN radio-
therapy before or after resection, and most of them had
stage IIIB disease (69.6%, 16/23). The percentages of
patients receiving radiotherapy in the excisional and in-
cisional biopsy groups were 11.7 (19/163) and 10.3%
(4/39), respectively.
The median follow-up time was 9.3 months. At the final
follow-up date, May 11, 2014, 171 (84.7%) patients
had died. The median OS was 10.7 months (95% CI
8.7–12.7 months) for all patients. There was no significant
difference between the excisional (OS = 10.9 months,
95% CI 8.7–13.2) and incisional biopsy groups (OS =
10.1 months, 95% CI 6.3–13.9), P = 0.569 (Fig. 1a), and
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the 1-year survival rates, 46.0 vs. 47.0%, respectively. In
subgroup analysis, OS did not show any difference be-
tween the two groups in either stage IIIB (11.2 vs.
9.0 months, P = 0.350) or stage IV (10.6 vs. 10.2 months,
P = 0.828) patients (Fig. 1b, c).
Multivariable analysis using a Cox proportional haz-
ards model showed that a PS ≥2 (HR = 2.75, 95% CI
1.71–4.38, P < 0.001) indicated a worse prognosis. An
EGFR mutation (HR = 0.58, 95% CI 0.40–0.84, P = 0.004)
and receiving systemic treatment (HR = 0.36, 95% CI
Table 1 Baseline demographic and clinical characteristics
Characteristics Excisional biopsy Incisional biopsy Total P value
(n = 163) (n = 39) (n = 202)
Sex 0.003
Male 92 (56.4%) 32 (82.1%) 124 (61.4%)
Female 71 (43.6%) 7 (17.9%) 78 (38.6%)
Age 0.922
Median 58 (26–85) 58 (29–75) 58 (26–85)
<65 110 (67.5%) 26 (66.7%) 136 (67.3%)
≥65 53 (32.5%) 13 (33.3%) 66 (32.7%)
Smoking status 0.008
Never-smoker 93 (57.1%) 13 (33.3%) 106(52.5%)
Current/ever-smoker 70(42.9%) 26(66.7%) 96 (47.5%)
ECOG PS 1.000a
PS 0–1 143 (87.7%) 35 (89.7%) 178 (88.1%)
PS ≥2 20 (12.3%) 4 (10.3%) 24 (11.9%)
Histology 0.747
Adenocarcinoma 138 (84.7%) 31 (79.5%) 169 (83.7%)
Squamous 13 (8.0%) 4 (10.3%) 17 (8.4%)
Large cell 7 (4.3%) 2 (5.1%) 9 (4.5%)
Other NSCLC 5 (3.1%) 2 (5.1%) 7 (3.5%)
Stage 0.448
IIIB 29 (17.8%) 9 (23.1%) 38 (18.8%)
IV 134 (82.2%) 30 (76.9%) 164 (81.2%)
LN size <0.001
Mean size 18.6 mm 25.9 mm 20.0 mm
>2 cm 34 (20.9%) 23 (59.0%) 57 (28.2%)
≤2 cm 129 (79.1%) 16 (41.0%) 145 (71.8%)
LN site 0.107
Unilateral 132 (81.0%) 27 (69.2%) 159 (78.7%)
Bilateral 31 (19.0%) 12 (30.8%) 43 (21.3%)
LN number 0.109
Single 77 (47.2%) 24 (61.5%) 101 (50.0%)
Multiple 86 (52.8%) 15 (38.5%) 101 (50.0%)
Fixed LN <0.001
Fixed 119 (73.0%) 6 (15.4%) 125 (61.9%)
Unfixed 44 (27.0%) 33 (84.6%) 77 (38.1%)
Systemic treatment 0.141
Yes 127 (77.9%) 26 (66.7%) 153 (75.7%)
No 36 (22.1%) 13 (33.3%) 49 (24.3%)
ECOG PS Eastern Cooperative Oncology Group performance status, LN lymph node
aFisher’s exact test
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0.25–0.53, P < 0.001) were independent prognostic fac-
tors (Table 2). Neither the number (multiple vs. single,
P = 0.225) nor site (bilateral vs. unilateral, P = 0.414) of
SCLNs was associated with an unfavorable OS. Similarly,
neither lymph node size (P = 0.906) nor fixed SCLN
(P = 0.847) was associated with an unfavorable OS.
Among evaluable patients, 11.8% (10/85) were ob-
served to have local recurrence after biopsy in the ex-
cisional biopsy group, and 16.7% (3/18) of patients
suffered local progression in the incisional biopsy group,
although the difference was not statistically significant;
P = 0.695.
Postoperative and intraoperative complications occurred
in 26 patients (12.9%). There was no difference in the exci-
sional (20/163, 12.3%) and incisional biopsy groups (6/39,
15.4%); P = 0.602. The most common complication was
postoperative pain, which accounted for 61.5% (16/26).
Most complications occurred on the first postoperative
day. The incidence of intraoperative bleeding, which was
the most dangerous complication, tended to favor the inci-
sional (5.1%) rather than the excisional biopsy group
(0.6%); however, the difference was not statistically signifi-
cant (P = 0.096). Complications such as exudation and
swelling favored the excisional biopsy group; however,
these differences did not reach statistical significance
(Table 3). One patient who received an excisional biopsy
suffered a cerebral infarction on the first postoperative
day, and his condition worsened; he lived only 2.9 months.
Another patient in the excisional biopsy group suffered a
wound infection and dehiscence; however, the wound
healed after drainage and antibiotic treatment. No other
serious adverse events accrued, and none died because of
the supraclavicular lymphadenectomy.
Discussion
To our knowledge, this was the first study to explore the
prognosis of SCLN-biopsied lung cancer patients. Patient
outcomes suggested that SCLN incisional biopsies were
safe and feasible and had no influence on the prognosis of
advanced NSCLC patients.
Many factors might affect the prognosis of lung cancer.
One of the most important factors is clinical stage [1].
This means that the survival of lung cancer mainly de-
pends on the M and N stages for stages IV and IIIB pa-
tients, respectively. Collaud et al. found that the prognosis
of lung cancer patients with microscopic residual tumor
after resection was poorer than curative resection in stages
I and II disease, but the difference was not observed in
stage III or IV disease [11]. All patients in this study had
stage IV or IIIB disease, with stage IV patients accounting
for the majority in this study, which may be the main rea-
son why SCLN incisional biopsies were not related to an
unfavorable prognosis. Nevertheless, our study indicated
that OS did not show any difference between the two
groups for stage IIIB patients. Because of the small sample
size of stage IIIB patients, further studies are necessary to
confirm this result.
Patients who received incisional biopsy in our study
tended to have SCLNs that were of a larger or fixed size
and were bulky. Bulky or fixed multi-station N2 was de-
fined as IIIA4 disease for which surgery was not indicated,
and which was related to a poor prognosis [12]. Previous
Fig. 1 a Kaplan–Meier curves of overall survival in all patients, b overall survival in stage IIIB patients, c and overall survival in stage IV patients
Table 2 Multivariable analysis for independent factors on
overall survival
Variable HR (95% CI) P value
ECOG PS (≥2 vs. <2) 2.75 (1.71–4.38) P < 0.001
EGFR (mutation vs. wild type) 0.58 (0.40–0.84) P = 0.004
Systemic treatment (yes vs. no) 0.36 (0.25–0.53) P = 0.001
Table 3 Complications in excisional biopsy group and incisional
biopsy group
Complications Excisional biopsy Incisional biopsy P value
(n = 163) (n = 39)
Pain 12 (7.4%) 4 (10.3%) 0.518
Bleeding 1 (0.6%) 2 (5.1%) 0.096
Swelling 5 (3.1%) 0 (0.0%) 0.585
Exudation 5 (3.1%) 0 (0.0%) 0.585
Othera 3 (1.8%) 0 (0.0%) 1.000
Total 20 (12.3%) 6 (15.4%) 0.602
aCerebral infarction (n = 1); fever (n = 1); wound infection (n = 1)
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studies revealed that multiple station N1 or N2 lymph
node metastasis was a poor prognostic factor compared
with single lymph node metastasis in non-advanced lung
cancer [13, 14]. There were no data for N3 lung cancer
previously, although Johnson and colleagues found that
lymph node number may affect prognosis in stage IIIB/
IIIC colon cancer [15]. We found that both the number
and size of SCLNs were not associated with an unfavor-
able OS in advanced NSCLC, nor was the SCLN site or
fixed lymph nodes.
We also found that the incidence of complications was
not significantly different between the two groups. The
intraoperative bleeding in the incisional biopsy group
(5.1%) seemed more common than that in the excisional
biopsy group (0.6%), though statistical significance was
not reached. This may be because there were more pa-
tients with bulky lymph nodes in the incisional biopsy
group, which may have increased the surgical difficulty.
The choice of biopsy techniques in melanoma has been
a controversial issue for decades. Much of the evidence has
tended to show that incisional biopsies do not influence
the prognosis of melanoma [2–4]. Despite this, an exci-
sional biopsy was still recommended as the priority biopsy
method in melanoma [16]. One important reason was that
incisional biopsies increased the risk of underdiagnosis in
melanoma and other tumors [17–19]. All patients enrolled
in our study were confirmed pathologically as SCLN
metastatic; therefore, we did not calculate the rate of
underdiagnosis. However, it should be noted that we
could obtain sufficient tissue from a resection biopsy
rather than a needle biopsy for pathologic diagnosis and
biomarker detection.
Another problem was that some investigators were
concerned that incisional biopsies might increase the
risk of cancer cell seeding and dissemination [20, 21].
Pisters et al. found that a positive surgical margin was
an independent adverse prognostic factor for local recur-
rence and survival in soft tissue sarcomas [22]. Park et
al. found that the major failure pattern for incomplete
resection of NSCLC was distant metastasis, despite the
postoperative radiotherapy and chemotherapy [23].Fur-
thermore, investigators found that the CT-guide re-
quired for a biopsy in lung cancer could increase the
risk of pleural seeding, though the incidence was low [24].
Our study showed that local progression (16.7%) in the in-
cisional biopsy group was slightly higher than local recur-
rence (11.8%) in the excisional biopsy group, but the
difference was not statistically significant. Nevertheless,
further studies are warranted to explore whether SCLN in-
cisional biopsies could lead to metastasis or dissemination
in advanced lung cancer.
The main limitation of this study was its retrospective
nature, so it was inevitable that some incomplete and/or
censored data existed. In obtaining such results, it is not
our purpose to advocate the use of incisional biopsies;
we only provide evidence to show that this approach
does not result in a worse prognosis. In clinical practice,
supraclavicular lymph nodes with metastatic carcinoma
should be removed as much as possible, but for some
cases, wide resection range would increase the risk of
complications such as bleeding, lymphatic fistula. Fur-
thermore, since complete resection is mainly dependent
on a surgeon’s experience, our results would benefit for
the decision-making. Here, we suggest that incisional bi-
opsies would be performed only if complete excision
were infeasible or accompanied with higher risk of
complications
Conclusions
In conclusion, our results revealed for the first time that
SCLN incisional biopsies do not negatively influence the
prognosis of NSCLC patients. It is safe and feasible to
perform an SCLN incisional biopsy as a last resort in
lung cancer.
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